Dr. Sachin Kamal-Bahl, PhD, is President and Founder of SKB Consulting Inc which is a health economics and policy-consulting firm providing expertise in generation of scientifically rigorous evidence and development of novel approaches to address issues related to pharmaceutical costs, outcomes, value, innovation, and access.
Prior to founding SKB Consulting Inc., he was Vice President and Head of the Center for Health Systems Innovation at Pfizer. The Center created under his leadership and vision aimed to a) help the organization recognize the strategic implications of environmental issues impacting valuation of and access to its therapies; b) develop and test prototypes and consider systematically embedding them within internal processes of the company in order to better position it to demonstrate value and gain market access for assets at launch; and c) develop, execute, and evaluate innovative experimental approaches in order to address access, pricing, or valuation challenges for its key assets. During his tenure at Pfizer the Center accelerated the pipeline of approaches to solve for current environmental challenges – examples of which range from leveraging joint EMA/HTA advice pathways, EMA adaptive licensing approaches, and systematic patient engagement in order to optimize drug development planning and access at launch to identifying innovative pricing and financing solutions for new drugs including those for curative treatments such as gene therapies.
Before joining Pfizer in 2014, he held various leadership positions in the areas of health economics and outcomes research, market access, pricing, and HTA at Merck. He received numerous awards for his achievements at Merck and while at Pfizer was selected as the Pharm Execs Top 16 Emerging Pharma Leaders in 2016. He has also held adjunct appointments at the University of Pennsylvania’s Leonard Davis Institute of Health Economics and the University of Maryland’s School of Pharmacy; served on advisory boards of initiatives led by professional societies such as ISPOR and organizations such as IVI and IBM Watson; and is a frequently invited speaker for panels and keynotes at external conferences. In addition to numerous peer- reviewed publications, he has published several high profile blogs and opinion pieces in Health Affairs, Forbes, and Harvard Business Review.